Identifying barriers to third-line therapy: a patient-centered approach to refractory overactive bladder

被引：0
|
作者：
Davenport, A. [1 ,2 ]
Stark, S. [2 ,5 ]
Quian, A. [1 ]
Sheyn, D. [1 ,3 ,4 ]
Mangel, J. [1 ]
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Metrohlth Med Ctr, Obstet & Gynecol, Cleveland, OH USA
[3] Metrohlth Med Ctr, Female Pelv Med & Reconstruct Surg, Cleveland, OH USA
[4] Univ Hosp Cleveland Med Ctr, Female Pelv Med & Reconstruct Surg, Cleveland, OH USA
[5] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2019年 / 220卷 / 03期
关键词：
D O I：
10.1016/j.ajog.2019.01.044
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
15
引用
收藏
页码：S716 / S716
页数：1
相关论文
共 50 条
  • [41] Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease
    Ansai, Hideto
    Masuda, Hiroshi
    Nakao, Hiro
    Nishimura, Nao
    Kubota, Mitsuru
    [J]. PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [42] Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML
    Caocci, Giovanni
    Atzeni, Sandra
    La Nasa, Giorgio
    [J]. CLINICAL MANAGEMENT ISSUES, 2012, 6 : 15 - 18
  • [43] Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory Urgency Urinary Incontinence)?
    Schneider M.P.
    Tubaro A.
    Burkhard F.C.
    [J]. Current Bladder Dysfunction Reports, 2018, 13 (3) : 158 - 161
  • [44] NATIONAL TRENDS IN THIRD-LINE TREATMENT FOR OVERACTIVE BLADDER AMONG COMMERCIALLY INSURED WOMEN, 2010-2019
    Edge, Preston
    Scioscia, Nicholas
    Yanek, Lisa
    Handa, Victoria
    [J]. NEUROUROLOGY AND URODYNAMICS, 2023, 42 : S110 - S110
  • [45] National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019
    Edge, Preston
    Scioscia, Nicholas F.
    Yanek, Lisa R.
    Handa, Victoria L.
    [J]. UROLOGY, 2023, 175 : 56 - 61
  • [46] THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2022, 54 : S93 - S94
  • [47] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [48] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [49] Third-line Therapy for Patients with metastatic castration-refractory Prostate Cancer (mCRPC)
    Rexer, H.
    Hammerer, P.
    Merseburger, A.
    [J]. AKTUELLE UROLOGIE, 2019, 50 (02) : 144 - 145
  • [50] Treatment of relapsed or refractory follicular Lymphoma Tisagenlecleucel: EU Approval as Third-line Therapy
    Ruedesheim, Sabine M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
12345